NeuroMolecular Medicine

, Volume 16, Issue 1, pp 61–69

Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review

  • Taro Kishi
  • Tomohiko Mukai
  • Yuki Matsuda
  • Nakao Iwata
Original Paper
First Online:
Received:
Accepted:

Abstract

Double-blinded, randomized, placebo-control trials of selective serotonin 3 receptor antagonists (5-HT3R-ANTs) for schizophrenia have differed in outcome. This meta-analysis tests the hypothesis that 5-HT3R-ANTs are effective for the treatment for schizophrenia. We searched PubMed, the Cochrane Library database, and PsycINFO up to June 15, 2013. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing 5-HT3R-ANTs add-on therapy with placebo. The risk ratio (RR), 95 % confidence intervals (CI), and standardized mean difference (SMD) were calculated. A random-effects model was used. Six studies (total n = 311) were identified. These included one granisetron plus risperidone study, one ondansetron plus risperidone study, one ondansetron plus haloperidol, and three tropisetron plus risperidone studies. The statistically significant effects of 5-HT3R-ANTs add-on therapy on Positive and Negative Syndrome Scale (PANSS) total scores were SMD = −1.03, CI = −1.70 to −0.36, p = 0.003 (I2 = 82 %, 5 studies, n = 261); on negative scores were SMD = −1.10, CI = −1.82 to −0.39, p = 0.002 (I2 = 84 %, 5 studies, n = 261); and on PANSS general scores were SMD = −0.70, CI = −1.23 to −0.17, p = 0.01 (I2 = 73 %, 5 studies, n = 261). However, 5-HT3R-ANTs add-on therapy was not superior to placebo in PANSS positive scores (SMD = −0.12, p = 0.33). Dropout due to all cause (RR = 0.80, p = 0.50), inefficacy (RR = 0.76, p = 0.65), or adverse events (RR = 0.84, p = 0.75) was similar in both groups. Constipation occurred significantly more often with 5-HT3R-ANTs than placebo (RR = 2.05, CI = 1.07–3.91, p = 0.03, NNH = 11, p = 0.02). 5-HT3R-ANTs add-on therapy is more beneficial on the psychopathology (especially negative symptoms) than controls in patients with schizophrenia, and 5-HT3R-ANTs seem to be well-tolerated treatments.

Keywords

Schizophrenia Serotonin 3 receptor antagonists Meta-analysis Granisetron Ondansetron Tropisetron 

References

  1. Akhondzadeh, S., Mohammadi, N., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Jamshidi, A. H., et al. (2009). Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophrenia Research, 107(2–3), 206–212.CrossRefPubMedGoogle Scholar
  2. Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., et al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 71–93.CrossRefPubMedGoogle Scholar
  3. Chouinard, G., & Margolese, H. C. (2005). Manual for the extrapyramidal symptom rating scale (ESRS). Schizophrenia Research, 76(2–3), 247–265.CrossRefPubMedGoogle Scholar
  4. Cohn, L. D., & Becker, B. J. (2003). How meta-analysis increases statistical power. Psychological Methods, 8(3), 243–253.CrossRefPubMedGoogle Scholar
  5. Conley, R. R., & Kelly, D. L. (2001). Management of treatment resistance in schizophrenia. Biological Psychiatry, 50(11), 898–911.CrossRefPubMedGoogle Scholar
  6. Conley, R. R., Tamminga, C. A., Kelly, D. L., & Richardson, C. M. (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry, 46(1), 73–77.CrossRefPubMedGoogle Scholar
  7. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188.CrossRefPubMedGoogle Scholar
  8. Hagan, R. M., Kilpatrick, G. J., & Tyers, M. B. (1993). Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl), 112(1 Suppl), S68–S75.CrossRefGoogle Scholar
  9. Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. British Medical Journal, 327(7414), 557–560.CrossRefPubMedGoogle Scholar
  10. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.CrossRefPubMedGoogle Scholar
  11. Karlin, A., & Akabas, M. H. (1995). Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron, 15(6), 1231–1244.CrossRefPubMedGoogle Scholar
  12. Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The Positive And Negative Syndrome Scale (PANSS): Rationale and standardisation. The British journal of psychiatry. Supplement, 7, 59–67.PubMedGoogle Scholar
  13. Khodaie-Ardakani, M. R., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., et al. (2013). Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research, 47(4), 472–478.CrossRefPubMedGoogle Scholar
  14. Kishi, T., Matsuda, Y., Nakamura, H., & Iwata, N. (2013a). Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. Journal of Psychiatric Research, 47(2), 149–154.CrossRefPubMedGoogle Scholar
  15. Kishi, T., Meltzer, H. Y., & Iwata, N. (2013b). Augmentation of antipsychotic drug action by azapirone serotonin 1A receptor partial agonists: A meta-analysis. The international journal of neuropsychopharmacology, 16(6), 1259–1266.CrossRefPubMedGoogle Scholar
  16. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373(9657), 31–41.CrossRefPubMedGoogle Scholar
  17. Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., et al. (2013). A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology, 38(6), 968–975.CrossRefPubMedGoogle Scholar
  18. Meltzer, H. Y. (1997). Treatment-resistant schizophrenia—the role of clozapine. Current Medical Research and Opinion, 14(1), 1–20.CrossRefPubMedGoogle Scholar
  19. Meltzer, H. Y. (2012). Serotonergic mechanisms as targets for existing and novel antipsychotics. Handbook of experimental pharmacology, 212, 87–124.CrossRefPubMedGoogle Scholar
  20. Meltzer, H. Y. (2013). Update on typical and atypical antipsychotic drugs. Annual Review of Medicine, 64, 393–406.CrossRefPubMedGoogle Scholar
  21. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry, 17(12), 1206–1227.CrossRefPubMedGoogle Scholar
  22. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. British Medical Journal, 339, b2535.CrossRefPubMedCentralPubMedGoogle Scholar
  23. Noroozian, M., Ghasemi, S., Hosseini, S. M., Modabbernia, A., Khodaie-Ardakani, M. R., Mirshafiee, O., et al. (2013). A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl). doi:10.1007/s00213-013-3064-2.
  24. Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., et al. (2010). A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry, 9, 27.CrossRefPubMedCentralPubMedGoogle Scholar
  25. Singh, S. P., Singh, V., Kar, N., & Chan, K. (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. British Journal of Psychiatry, 197(3), 174–179.CrossRefPubMedGoogle Scholar
  26. Wolf, H. (2000). Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scandinavian Journal of Rheumatology. Supplement, 113, 37–45.CrossRefPubMedGoogle Scholar
  27. Zhang, Z. J., Kang, W. H., Li, Q., Wang, X. Y., Yao, S. M., & Ma, A. Q. (2006). Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study. Schizophrenia Research, 88(1–3), 102–110.CrossRefPubMedGoogle Scholar
  28. Zhang, X. Y., Liu, L., Liu, S., Hong, X., da Chen, C., Xiu, M. H., et al. (2012). Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. American Journal of Psychiatry, 169(9), 974–981.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Taro Kishi
    • 1
  • Tomohiko Mukai
    • 1
  • Yuki Matsuda
    • 1
  • Nakao Iwata
    • 1
  1. 1.Department of PsychiatryFujita Health University School of MedicineToyoakeJapan

Personalised recommendations